<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:mpath ids='MPATH_3'>Apoptosis</z:mpath> plays an important role in <z:e sem="disease" ids="C0027671" disease_type="Neoplastic Process" abbrv="">neoplastic processes</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3 </plain></SENT>
<SENT sid="2" pm="."><plain>The expression pattern of this protein in human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> has not been reported </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: We investigated Bcl-B expression in <z:mpath ids='MPATH_458'>normal</z:mpath> human tissues and several types of human epithelial and nonepithelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> by immunohistochemistry, correlating results with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage, histologic grade, and patient survival </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Bcl-B protein was strongly expressed in <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_458'>normal</z:mpath> plasma cells but found in only 18% of <z:hpo ids='HP_0006775'>multiple myelomas</z:hpo> (n = 133) </plain></SENT>
<SENT sid="5" pm="."><plain>Bcl-B immunostaining was also present in <z:mpath ids='MPATH_458'>normal</z:mpath> germinal center centroblasts and centrocytes and in approximately half of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 48) specimens, whereas follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (n = 57) did not contain Bcl-B </plain></SENT>
<SENT sid="6" pm="."><plain>In breast (n = 119), prostate (n = 66), gastric (n = 180), and colorectal (n = 106) <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, as well as in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancers</z:e> (n = 82), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific overexpression of Bcl-B was observed </plain></SENT>
<SENT sid="7" pm="."><plain>Bcl-B expression was associated with variables of poor prognosis, such as high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location (P = 0.02) of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, as well as with greater incidence of <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (P = 0.005) and shorter survival of patients with <z:e sem="disease" ids="C0149925" disease_type="Neoplastic Process" abbrv="SCLC">small cell lung cancer</z:e> (P = 0.009) </plain></SENT>
<SENT sid="8" pm="."><plain>Conversely, although overexpressed in many <z:hpo ids='HP_0012126'>gastric cancers</z:hpo>, Bcl-B tended to correlate with better outcome (P = 0.01) and more differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> histology (P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>-specific alterations in Bcl-B expression may define subsets of nonepithelial and epithelial <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with distinct clinical behaviors </plain></SENT>
</text></document>